Skip to main
NTRA
NTRA logo

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 35%
Buy 59%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Natera Inc. demonstrated significant growth in its Signatera clinical units, reporting approximately 181,000 units for the quarter, which represents an increase of about 20,000 units sequentially and exceeds earlier estimates. The company has also raised its gross margin guidance to a range of 61% to 64%, indicating improved average selling price trends and expectations for increased adoption of the Signatera test among first-time patients. These positive developments suggest a robust demand for Natera's diagnostic offerings, contributing to a favorable outlook for the company's financial performance.

Bears say

Natera Inc. is facing significant challenges due to its ongoing cash burn and lack of profitability, which raises concerns about its financial sustainability. The company relies heavily on reimbursement for its diagnostic tests, and any inability to secure such reimbursement or a reduction in reimbursement rates could severely impact its financial results. Additionally, concerning findings regarding the outcomes of transplant patients could hinder the adoption of its Prospera test and likely dampen overall market confidence in the company's product efficacy.

Natera (NTRA) has been analyzed by 17 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 59% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 17 analysts, Natera (NTRA) has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $192.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $192.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.